< Back to previous page
Researcher
Michel Delforge
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Hematology (Division)
Member
From1 Jan 2021 → Today - Stem Cell and Developmental Biology (Division)
Member
From1 Apr 2013 → 31 Dec 2020 - Faculty of Medicine (Faculty)
Member
From1 Oct 2000 → 30 Sep 2002
Projects
1 - 10 of 19
- Ultra-sensitive minimal residual disease assessment by blood-based clonotypic mass spectrometry approach in plasma cell dyscrasias (MASSIAS)From1 Jan 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Optimizing the use of bispecific antibody treatment in Multiple Myeloma by studying the immune microenvironment and cellular mechanisms of drug resistance.From1 Oct 2023 → TodayFunding: FWO Strategic Basic Research Grant
- Ultra-sensitive minimal residual disease assessment by blood-based clonotypic mass spectrometry approach in plasma cell dyscrasias (MASSIAS)From1 Oct 2023 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Positron emission tomography combined with innovative laboratory techniques for improved risk and disease assessment in myeloma.From1 Jan 2021 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Risk prediction and modeling of cancer therapy related cardiotoxicityFrom1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Atomic Force Microscopy Enhanced Spectroscopy to Study Strains and Seeding of Amyloids In SituFrom1 May 2020 → TodayFunding: FWO Medium Size Research Infrastructure
- Augmenting THherapeutic Effectiveness through Novel AnalyticsFrom1 Apr 2020 → 31 Dec 2023Funding: VLAIO - Personalised Medicine ICON
- Het KU Leuven Kankerinstituut (LKI): interdisciplinaire samenwerking ter bevordering van kankeronderzoek, kankerbehandeling en –zorg.From1 Jan 2020 → TodayFunding: BOF - research organisations
- Unravelling the mechanisms of drug resistance to proteasome inhibitors to optimize treatment in patients with multiple myeloma.From1 Jul 2019 → 30 Jun 2023Funding: Foundations, funds and other with scientific goal
Publications
31 - 40 of 265
- Recommendations on the management of multiple myeloma in 2020(2022)
Authors: Lucienne Michaux, Michel Delforge
Pages: 445 - 461 - Combined lenalidomide/bortezomib for multiple myeloma complicated by fulminant myocarditis: a rare case report of widely used chemotherapy(2022)
Authors: Peter Vandenberghe, Michel Delforge, Christophe Vandenbriele
- Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma(2022)
Authors: Michel Delforge
Pages: 1309 - 1318 - Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies.(2022)
Authors: Michel Delforge
Pages: 864 - Case report: Two sisters with light-chain cardiac amyloidosis, a mere coincidence?(2022)
Authors: Sarah Cappuyns, Alexander Van De Bruaene, Jan Bogaert, Lucienne Michaux, Michel Delforge
- Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients(2022)
Authors: Michel Delforge, Peter Vandenberghe
Pages: 243 - 250 - Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 32, pg 309, 2021)(2022)
Authors: Michel Delforge
Pages: 117 - 117 - COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network(2021)
Authors: Michel Delforge
Pages: E934 - E946 - Real-World Outcomes for Standard-ofCare Treatments in Patients with Relapsed/Refractory Multiple Myeloma(2021)
Authors: Michel Delforge
- A Multi-Center, Phase 1b Study to Assess the Safety, Pharmacokinetics and Efficacy of Subcutaneous Isatuximab Plus Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma(2021)
Authors: Michel Delforge
Patents
1 - 2 of 2
- Cell therapy for myelodysplastic syndromes (Inventor)
- CELL THERAPY FOR MYELODYSPLASTIC SYNDROMES (Inventor)